S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
NASDAQ:BDSI

BioDelivery Sciences International Stock Forecast, Price & News

$3.72
-0.01 (-0.27 %)
(As of 09/24/2021 04:00 PM ET)
Add
Compare
Today's Range
$3.66
$3.77
50-Day Range
$3.43
$4.34
52-Week Range
$3.04
$4.99
Volume584,118 shs
Average Volume918,988 shs
Market Capitalization$366.78 million
P/E Ratio11.27
Dividend YieldN/A
Beta0.7
30 days | 90 days | 365 days | Advanced Chart
Receive BDSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BioDelivery Sciences International and its competitors with MarketBeat's FREE daily newsletter.


BioDelivery Sciences International logo

About BioDelivery Sciences International

BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. Its products include Symproic and Belbuca. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.66 out of 5 stars

Medical Sector

53rd out of 1,351 stocks

Pharmaceutical Preparations Industry

24th out of 664 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 3.1 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions

Is BioDelivery Sciences International a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BioDelivery Sciences International stock.
View analyst ratings for BioDelivery Sciences International
or view top-rated stocks.

What stocks does MarketBeat like better than BioDelivery Sciences International?

Wall Street analysts have given BioDelivery Sciences International a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioDelivery Sciences International wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is BioDelivery Sciences International's next earnings date?

BioDelivery Sciences International is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for BioDelivery Sciences International
.

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) issued its earnings results on Tuesday, August, 3rd. The specialty pharmaceutical company reported $0.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.05 by $0.04. The specialty pharmaceutical company earned $41.44 million during the quarter, compared to the consensus estimate of $42.02 million. BioDelivery Sciences International had a net margin of 20.65% and a trailing twelve-month return on equity of 31.75%.
View BioDelivery Sciences International's earnings history
.

How has BioDelivery Sciences International's stock been impacted by COVID-19?

BioDelivery Sciences International's stock was trading at $3.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BDSI shares have decreased by 6.1% and is now trading at $3.72.
View which stocks have been most impacted by COVID-19
.

What guidance has BioDelivery Sciences International issued on next quarter's earnings?

BioDelivery Sciences International updated its third quarter 2021 earnings guidance on Tuesday, September, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $38 million-$42 million, compared to the consensus revenue estimate of $44.07 million.

What price target have analysts set for BDSI?

3 Wall Street analysts have issued 1 year price objectives for BioDelivery Sciences International's stock. Their forecasts range from $6.00 to $10.00. On average, they anticipate BioDelivery Sciences International's stock price to reach $7.42 in the next year. This suggests a possible upside of 99.4% from the stock's current price.
View analysts' price targets for BioDelivery Sciences International
or view top-rated stocks among Wall Street analysts.

Who are BioDelivery Sciences International's key executives?

BioDelivery Sciences International's management team includes the following people:
  • Jeffrey Allen Bailey, Chief Executive Officer & Director
  • Scott M. Plesha, President & Chief Commercial Officer
  • Joseph Lockhart, Senior Vice President-Operations
  • Mary Theresa Coelho, CFO, Treasurer & Executive Vice President
  • Thomas B. Smith, Chief Medical Officer

What other stocks do shareholders of BioDelivery Sciences International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), JD.com (JD), Baidu (BIDU), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

Who are BioDelivery Sciences International's major shareholders?

BioDelivery Sciences International's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.55%), Wasatch Advisors Inc. (5.63%), Vanguard Group Inc. (5.08%), Systematic Financial Management LP (3.99%), State Street Corp (2.32%) and Goldman Sachs Group Inc. (1.99%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Jeffrey Allen Bailey, Kevin Kotler, Mark A Sirgo, Mary Theresa Coelho, Scott M Plesha, Thomas B Smith and W Mark Watson.
View institutional ownership trends for BioDelivery Sciences International
.

Which institutional investors are selling BioDelivery Sciences International stock?

BDSI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Goldman Sachs Group Inc., Blair William & Co. IL, Vanguard Group Inc., Wells Fargo & Company MN, Nuveen Asset Management LLC, Algert Global LLC, and Bank of America Corp DE. Company insiders that have sold BioDelivery Sciences International company stock in the last year include James Vollins, Jeffrey Allen Bailey, and Mary Theresa Coelho.
View insider buying and selling activity for BioDelivery Sciences International
or view top insider-selling stocks.

Which institutional investors are buying BioDelivery Sciences International stock?

BDSI stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Systematic Financial Management LP, State Street Corp, Dimensional Fund Advisors LP, American Century Companies Inc., GSA Capital Partners LLP, Panagora Asset Management Inc., and Dupont Capital Management Corp.
View insider buying and selling activity for BioDelivery Sciences International
or or view top insider-buying stocks.

How do I buy shares of BioDelivery Sciences International?

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioDelivery Sciences International's stock price today?

One share of BDSI stock can currently be purchased for approximately $3.72.

How much money does BioDelivery Sciences International make?

BioDelivery Sciences International has a market capitalization of $366.78 million and generates $156.47 million in revenue each year. The specialty pharmaceutical company earns $25.71 million in net income (profit) each year or $0.24 on an earnings per share basis.

How many employees does BioDelivery Sciences International have?

BioDelivery Sciences International employs 176 workers across the globe.

When was BioDelivery Sciences International founded?

BioDelivery Sciences International was founded in 1997.

What is BioDelivery Sciences International's official website?

The official website for BioDelivery Sciences International is www.bdsi.com.

Where are BioDelivery Sciences International's headquarters?

BioDelivery Sciences International is headquartered at 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612.

How can I contact BioDelivery Sciences International?

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at (919) 582-9050 or via email at [email protected].


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.